Selectively targeting FLT3-ITD mutants over FLT3-wt by a novel inhibitor for acute myeloid leukemia

Aoli Wang; Chen Hu; Cheng Chen; Xiaofei Liang; Beilei Wang; Fengming Zou; Kailin Yu; Feng Li; Qingwang Liu; Ziping Qi; Junjie Wang; Wenliang Wang; Li Wang; Ellen L Weisberg; Wenchao Wang; Lili Li; Jian Ge; Ruixiang Xia; Jing Liu; Qingsong Liu

doi:10.3324/haematol.2019.244186

Selectively targeting FLT3-ITD mutants over FLT3-wt by a novel inhibitor for acute myeloid leukemia

Haematologica. 2021 Feb 1;106(2):605-609. doi: 10.3324/haematol.2019.244186.

Authors

Aoli Wang¹, Chen Hu¹, Cheng Chen¹, Xiaofei Liang¹, Beilei Wang¹, Fengming Zou¹, Kailin Yu¹, Feng Li¹, Qingwang Liu¹, Ziping Qi¹, Junjie Wang¹, Wenliang Wang¹, Li Wang¹, Ellen L Weisberg², Wenchao Wang¹, Lili Li³, Jian Ge³, Ruixiang Xia³, Jing Liu¹, Qingsong Liu¹

Affiliations

¹ Chinese Academy of Sciences.
² Dana Farber Cancer Institute, Harvard Medical School.
³ Department of Hematology, the First Affiliated Hospital of Anhui Medical University.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / genetics
Mutation
Tandem Repeat Sequences / genetics
fms-Like Tyrosine Kinase 3 / genetics

Substances

FLT3 protein, human
fms-Like Tyrosine Kinase 3

Grants and funding

Funding: this work was supported by the National Natural Science Foundation of China (grant ns. 81773777, 81803366, 81872745, 81872748, 81673469), the “Personalized Medicines- Molecular Signature-Based Drug Discovery and Development”, Strategic Priority Research Program of the Chinese Academy of Sciences (grant n. XDA12020114), the National Science & Technology Major Project “Key New Drug Creation and Manufacturing Program” of China (grant n. 2018ZX09711002), the China Postdoctoral Science Foundation (grant ns. 2018T110634, 2018M630720, 2019M652057), the Postdoctoral Science Foundation of Anhui Province (grant ns. 2018B279, 2019B300, 2019B326), the Frontier Science Key Research Program of CAS (grant n. QYZDB-SSW-SLH037), the CASHIPS Director's Fund (grant n. BJPY2019A03), and the Key Program of 13th five-year plan of CASHIPS (grant n. KP-2017-26).